Restrictions will not be added to the US Food and Drug Administration’s additional coronavirus funding despite Republican efforts during a markup of the bill in the House Energy and Commerce Committee on 11 February.
US FDA COVID Funds Move Forward In Congress, No Strings Attached
Amendment to require one-firth of the money be devoted to therapeutic review was defeated by the House Energy and Commerce Committee.
More from Legislation
More from Pink Sheet
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
FDA Commissioner Martin Makary was sworn in Friday and knew of the plan that ultimately lead to CBER director Peter Marks' resignation on 28 March.